论文部分内容阅读
Accumulating evidence suggests that anticancer chemotherapeutic success relies on the elicitation of a durable tumor-targeting immune response following "immunogenic" tumor cell death.Loss-of-function mutations in immune-related genes have been associated with poor clinical outcome of cancer patients.